{"id":"matching-placebo-to-pioglitazone","safety":{"commonSideEffects":[{"rate":"null","effect":"Weight gain"},{"rate":"null","effect":"Fluid retention / edema"},{"rate":"null","effect":"Hypoglycemia"},{"rate":"null","effect":"Heart failure exacerbation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pioglitazone works by binding to and activating PPAR-γ, a nuclear receptor involved in glucose and lipid metabolism. This activation increases insulin sensitivity in muscle and adipose tissue, reducing hepatic glucose production and improving glycemic control in type 2 diabetes. The matching placebo is an inert formulation designed to be indistinguishable from active pioglitazone for blinded trial purposes.","oneSentence":"This is a placebo control arm matching pioglitazone, a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:19.142Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus (placebo control in phase 3 trial)"}]},"trialDetails":[{"nctId":"NCT06922656","phase":"PHASE4","title":"Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?","status":"NOT_YET_RECRUITING","sponsor":"Dasman Diabetes Institute","startDate":"2025-09-15","conditions":"Type 1 Diabetes","enrollment":60},{"nctId":"NCT06336798","phase":"PHASE2","title":"Bioenergetic Effect of Pioglitazone in CLD-PH","status":"RECRUITING","sponsor":"Emory University","startDate":"2024-12-17","conditions":"Pulmonary Hypertension, Pulmonary Hypertension Due to Lung Diseases","enrollment":20},{"nctId":"NCT00179400","phase":"PHASE4","title":"The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2000-12","conditions":"Type 2 Diabetes Mellitus","enrollment":26},{"nctId":"NCT04227093","phase":"PHASE4","title":"Acetazolamide Add-On Therapy to OSA Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2020-01-22","conditions":"Obstructive Sleep Apnea","enrollment":26},{"nctId":"NCT02535832","phase":"PHASE1","title":"Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2015-09","conditions":"Rheumatoid Arthritis, Insulin Resistance","enrollment":16},{"nctId":"NCT00203996","phase":"PHASE4","title":"Polycystic Ovary Syndrome (PCOS) and Sleep Apnea","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2003-09","conditions":"Polycystic Ovary Syndrome, Obstructive Sleep Apnea","enrollment":37},{"nctId":"NCT03910361","phase":"PHASE4","title":"Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2019-04-12","conditions":"Type2 Diabetes, Non-Alcoholic Fatty Liver Disease","enrollment":51},{"nctId":"NCT01931566","phase":"PHASE3","title":"Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset","status":"TERMINATED","sponsor":"Takeda","startDate":"2013-08-01","conditions":"Mild Cognitive Impairment Due to Alzheimer's Disease","enrollment":3494},{"nctId":"NCT02284906","phase":"PHASE3","title":"AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease","status":"TERMINATED","sponsor":"Takeda","startDate":"2015-02-12","conditions":"Mild Cognitive Impairment Due to Alzheimer's Disease","enrollment":40},{"nctId":"NCT02231021","phase":"PHASE4","title":"The Practical Evidence of Antidiabetic Combination Therapy in Korea","status":"COMPLETED","sponsor":"Kun-Ho Yoon","startDate":"2014-09","conditions":"Type 2 Diabetes Mellitus","enrollment":216},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":585},{"nctId":"NCT01217073","phase":"PHASE2","title":"A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-10-08","conditions":"Type 2 Diabetes Mellitus","enrollment":685},{"nctId":"NCT01431521","phase":"PHASE1","title":"Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-26","conditions":"Non-alcoholic Fatty Liver Disease","enrollment":31},{"nctId":"NCT00634036","phase":"PHASE2","title":"Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics","status":"COMPLETED","sponsor":"Fernando Holguin","startDate":"2009-10","conditions":"Asthma","enrollment":23},{"nctId":"NCT00722371","phase":"PHASE3","title":"MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09-05","conditions":"Type 2 Diabetes Mellitus","enrollment":1615},{"nctId":"NCT01028391","phase":"PHASE3","title":"30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09-01","conditions":"Type 2 Diabetes Mellitus","enrollment":317},{"nctId":"NCT00541450","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":492},{"nctId":"NCT00397631","phase":"PHASE3","title":"Initial Combination With Pioglitazone Study (0431-064)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12-19","conditions":"Type 2 Diabetes Mellitus","enrollment":520},{"nctId":"NCT00086515","phase":"PHASE3","title":"Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06-30","conditions":"Diabetes Mellitus, Type II","enrollment":701},{"nctId":"NCT00879970","phase":"PHASE4","title":"Thiazolidinedione Intervention With Vitamin D Evaluation","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1332},{"nctId":"NCT01798706","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Type 2 Diabetes","enrollment":350},{"nctId":"NCT00683878","phase":"PHASE3","title":"Add-on to Thiazolidinedione (TZD) Failures","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-07","conditions":"Type 2 Diabetes","enrollment":972},{"nctId":"NCT01703260","phase":"PHASE2","title":"Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2013-06","conditions":"Nonalcoholic Steatohapatitis","enrollment":20},{"nctId":"NCT00839527","phase":"PHASE3","title":"A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2","enrollment":685},{"nctId":"NCT00763815","phase":"PHASE3","title":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-09","conditions":"Diabetes Mellitus Type 2","enrollment":484},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT00975286","phase":"PHASE3","title":"24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-10","conditions":"Type 2 Diabetes Mellitus","enrollment":446},{"nctId":"NCT02678676","phase":"","title":"An Observational Study of Patient Cohorts Who Previously Received Long-term Treatment With Pioglitazone or Placebo in Addition to Existing Antidiabetic Medications","status":"COMPLETED","sponsor":"Takeda","startDate":"2004-11","conditions":"Diabetes Mellitus, Type 2","enrollment":3599},{"nctId":"NCT00722917","phase":"PHASE2","title":"Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Takeda","startDate":"2008-07","conditions":"Diabetes Mellitus","enrollment":323},{"nctId":"NCT00086502","phase":"PHASE3","title":"Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06","conditions":"Diabetes Mellitus, Type 2","enrollment":353},{"nctId":"NCT00736996","phase":"PHASE2","title":"Pioglitazone Or Exercise to Treat Mild Cognitive Impairment (MCI)","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2008-11","conditions":"Mild Cognitive Impairment","enrollment":78},{"nctId":"NCT01280123","phase":"PHASE2","title":"Pioglitazone in Early Parkinson's Disease","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2011-03","conditions":"Parkinson's Disease","enrollment":210},{"nctId":"NCT01115712","phase":"PHASE1","title":"Effects of Pioglitazone on Insulin Sensitivity in Healthy Overweight and Obese Males (MK-0000-170)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05","conditions":"Healthy, Overweight, Obesity","enrollment":35},{"nctId":"NCT01103414","phase":"PHASE2","title":"Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Metabolic Solutions Development Company","startDate":"2010-09","conditions":"Type 2 Diabetes","enrollment":356},{"nctId":"NCT00814372","phase":"PHASE2","title":"Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2008-12","conditions":"Type 2 Diabetes Mellitus","enrollment":242},{"nctId":"NCT00787644","phase":"PHASE2","title":"Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)","status":"TERMINATED","sponsor":"University of Vermont","startDate":"2009-01","conditions":"Asthma, Obesity","enrollment":28},{"nctId":"NCT00153166","phase":"PHASE2, PHASE3","title":"ARREST PAD (Peripheral Arterial Disease)","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2004-01","conditions":"Arterial Occlusive Disease, Intermittent Claudication, Insulin Resistance","enrollment":76},{"nctId":"NCT00641043","phase":"PHASE3","title":"Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-03","conditions":"Diabetes Mellitus, Type 2","enrollment":389},{"nctId":"NCT01230749","phase":"PHASE2","title":"A Study of Multiple Oral Doses of JNJ-41443532 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-12","conditions":"Diabetes Mellitus, Type 2","enrollment":89},{"nctId":"NCT00443755","phase":"PHASE2","title":"Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2005-08","conditions":"Type 2 Diabetes, Insulin Resistance, Metabolic Syndrome","enrollment":28},{"nctId":"NCT01106690","phase":"PHASE3","title":"The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-06","conditions":"Diabetes Mellitus, Type 2","enrollment":344},{"nctId":"NCT00655863","phase":"PHASE3","title":"Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-07","conditions":"Diabetes Mellitus","enrollment":71},{"nctId":"NCT00328627","phase":"PHASE3","title":"Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-05","conditions":"Type 2 Diabetes Mellitus","enrollment":1554},{"nctId":"NCT00432276","phase":"PHASE3","title":"Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-01","conditions":"Diabetes Mellitus","enrollment":803},{"nctId":"NCT00395512","phase":"PHASE3","title":"Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-11","conditions":"Diabetes Mellitus","enrollment":655},{"nctId":"NCT01289119","phase":"PHASE3","title":"Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-12","conditions":"Diabetes Mellitus, Type 2","enrollment":506},{"nctId":"NCT01456117","phase":"PHASE1","title":"Study to Assess the Effects of Daily Administration of Pioglitazone on Brain Hemodynamics in Healthy Elderly Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-11","conditions":"Healthy","enrollment":61},{"nctId":"NCT00225264","phase":"PHASE3","title":"Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.","status":"COMPLETED","sponsor":"Takeda","startDate":"2003-10","conditions":"Diabetes Mellitus","enrollment":458},{"nctId":"NCT00676260","phase":"PHASE2","title":"Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin","status":"COMPLETED","sponsor":"Takeda","startDate":"2002-12","conditions":"Diabetes Mellitus","enrollment":29},{"nctId":"NCT00174993","phase":"PHASE3","title":"Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2001-05","conditions":"Diabetes Mellitus","enrollment":4373},{"nctId":"NCT00521742","phase":"PHASE3","title":"Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2001-03","conditions":"Diabetes Mellitus","enrollment":300},{"nctId":"NCT00331487","phase":"PHASE3","title":"Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia","status":"COMPLETED","sponsor":"Takeda","startDate":"2000-09","conditions":"Diabetes Mellitus","enrollment":719},{"nctId":"NCT00494312","phase":"PHASE4","title":"Safety Study of Pioglitazone Compared To Glyburide on Liver Function","status":"COMPLETED","sponsor":"Takeda","startDate":"2000-10","conditions":"Diabetes Mellitus, Liver","enrollment":2120},{"nctId":"NCT00521820","phase":"PHASE3","title":"Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects With Mild to Moderate Congestive Heart Failure","status":"TERMINATED","sponsor":"Takeda","startDate":"2000-06","conditions":"Diabetes Mellitus","enrollment":518},{"nctId":"NCT00762736","phase":"PHASE2","title":"Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2004-07","conditions":"Diabetes Mellitus","enrollment":704},{"nctId":"NCT00708175","phase":"PHASE4","title":"Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-05","conditions":"Bone Metabolism","enrollment":156},{"nctId":"NCT00286494","phase":"PHASE3","title":"Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-02","conditions":"Diabetes Mellitus","enrollment":493},{"nctId":"NCT00770653","phase":"PHASE3","title":"Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-04","conditions":"Diabetes Mellitus, Dyslipidemias","enrollment":305},{"nctId":"NCT00631007","phase":"PHASE2","title":"A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator","status":"COMPLETED","sponsor":"InteKrin Therapeutics, Inc.","startDate":"2008-02","conditions":"Type 2 Diabetes Mellitus","enrollment":367},{"nctId":"NCT00770640","phase":"PHASE2","title":"Efficacy of Pioglitazone and Insulin in Treating Subjects With Type 2 Diabetes Mellitus and Renal Failure.","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-08","conditions":"Diabetes Mellitus","enrollment":40},{"nctId":"NCT00770445","phase":"PHASE4","title":"Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With Insulin-Treated Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-05","conditions":"Diabetes Mellitus","enrollment":121},{"nctId":"NCT00770575","phase":"PHASE2","title":"Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating Subjects With Elevated Risk for Cardiovascular Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2005-06","conditions":"Cardiovascular Diseases","enrollment":148},{"nctId":"NCT00770952","phase":"PHASE3","title":"Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-12","conditions":"Diabetes Mellitus","enrollment":91},{"nctId":"NCT00771004","phase":"PHASE2","title":"Efficacy of Pioglitazone on Myocardial Function in Patients Undergoing Coronary Stent Implantation.","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-08","conditions":"Oxidative Stress, Coronary Artery Disease, Type 2 Diabetes","enrollment":63},{"nctId":"NCT00754403","phase":"PHASE4","title":"Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2005-07","conditions":"Diabetes Mellitus","enrollment":312},{"nctId":"NCT00770497","phase":"PHASE2","title":"Efficacy Study of Pioglitazone and Ramipril Combination Therapy in Treating Non-diabetic Hypertensive Patients.","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-03","conditions":"Inflammation, Hypertension","enrollment":172},{"nctId":"NCT00772174","phase":"PHASE3","title":"Efficacy and Safety Study of Pioglitazone Combined With Metformin on Metabolic Syndrome in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-01","conditions":"Diabetes Mellitus","enrollment":418},{"nctId":"NCT00227110","phase":"PHASE4","title":"Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2002-10","conditions":"Nonalcoholic Steatohepatitis","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":56,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Matching placebo to pioglitazone","genericName":"Matching placebo to pioglitazone","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control arm matching pioglitazone, a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity. Used for Type 2 diabetes mellitus (placebo control in phase 3 trial).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}